<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544063</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564073</org_study_id>
    <secondary_id>CLCC-XEL-IRIN-OX</secondary_id>
    <secondary_id>INCA-RECF0416</secondary_id>
    <secondary_id>VA-XIOX</secondary_id>
    <secondary_id>EudraCT-2005-004567-38</secondary_id>
    <nct_id>NCT00544063</nct_id>
  </id_info>
  <brief_title>Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>Phase I Study Evaluating the Feasibility of Chemotherapy With Capecitabine, Irinotecan, and Oxaliplatin in Patients With Metastatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin,&#xD;
      work in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when&#xD;
      given together with irinotecan and oxaliplatin in treating patients with metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicities of capecitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the recommended phase II dose of capecitabine.&#xD;
&#xD;
        -  Define the toxicity profile.&#xD;
&#xD;
        -  Evaluate potential antitumor activity in terms of objective response, duration of&#xD;
           response, and time to disease progression.&#xD;
&#xD;
        -  Evaluate the pharmacokinetic profile of capecitabine and irinotecan hydrochloride.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of capecitabine conducted in two parts.&#xD;
&#xD;
        -  Part I: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral&#xD;
           capecitabine twice daily on days 1-7. Treatment repeats every 2 weeks for up to 6 months&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of up to 6 patients receive escalating doses (up to 5 dosages) of capecitabine. The&#xD;
      maximum tolerated dose (MTD) is defined as the dose at which 50% of patients experience&#xD;
      toxicity during the first 2 courses of therapy.&#xD;
&#xD;
        -  Part II: Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV&#xD;
           over 90 minutes on day 1 and oral capecitabine on days 1-7. Treatment repeats every 2&#xD;
           weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of up to 6 patients receive escalating doses (up to 7 dosages) of capecitabine. The&#xD;
      MTD is defined as in part I.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of capecitabine</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended phase II dose of capecitabine</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of capecitabine and irinotecan hydrochloride</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic carcinoma&#xD;
&#xD;
               -  Primary tumor may be present&#xD;
&#xD;
               -  No curative therapy available or the patient achieved no response to prior&#xD;
                  standard therapy&#xD;
&#xD;
               -  Nonresectable metastatic disease&#xD;
&#xD;
          -  Measurable, evaluable, or nonevaluable disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Symptomatic brain metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.25 times upper limit of normal (ULN) (1.5 times ULN if due to liver&#xD;
             metastases)&#xD;
&#xD;
          -  Transaminases &lt; 3 times ULN (5 times ULN if due to liver metastases)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Severe concurrent infection or major organ failure, including any of the following:&#xD;
&#xD;
               -  Cardiac disease&#xD;
&#xD;
               -  Diabetic decompensation&#xD;
&#xD;
               -  Clinically active infection&#xD;
&#xD;
          -  Prior severe toxicity from fluorouracil&#xD;
&#xD;
          -  Intestinal obstruction or subobstruction&#xD;
&#xD;
          -  Malabsorption syndrome&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Uncontrolled epilepsy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  At least 4-6 weeks since prior anticancer chemotherapy&#xD;
&#xD;
        Exclusions criteria:&#xD;
&#xD;
          -  Prior chemotherapy with any of the study drugs&#xD;
&#xD;
          -  Prior major intestinal resection&#xD;
&#xD;
          -  Concurrent participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ychou, MD, PhD</last_name>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Ychou, MD, PhD</last_name>
      <phone>33-4-6761-3066</phone>
      <email>mychou@valdorel.fnclcc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>December 13, 2009</last_update_submitted>
  <last_update_submitted_qc>December 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

